ReviewCancer metastasis reviews2011
Cyclooxygenases and lipoxygenases in cancer.
Review in Cancer metastasis reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 159 citations in OpenAlex.
- The 5-Lipoxygenase Pathway in Ovarian Cancer: Mechanisms of Metastasis, Chemoresistance, and Translational Targeting.International journal of women's health · 2026Review
- Decoding lysophosphatidic acid signaling in physiology and disease: mapping the multimodal and multinodal signaling networks.Signal transduction and targeted therapy · 2025Review
- Is Deuterium Sequestering by Reactive Carbon Atoms an Important Mechanism to Reduce Deuterium Content in Biological Water?FASEB bioAdvances · 2025Review
- Arachidonic acid in aging: New roles for old players.Journal of advanced research · 2025Review
- 2-(4-Bromobenzyl) tethered 4-amino aryl/alkyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-RSC medicinal chemistry · 2025Article
- Identification of Novel Human 15-Lipoxygenase-2 (h15-LOX-2) Inhibitors Using a Virtual Screening Approach.Journal of medicinal chemistry · 2025Article
- Article
- Divergent gene expression ofFrontiers in oncology · 2025Article
- Pyrimidine Derivatives as Selective COX-2 Inhibitors with Anti-Inflammatory and Antioxidant Properties.International journal of molecular sciences · 2024Article
- Unveiling the multifaceted antiproliferative efficacy ofRSC advances · 2024Article
- Arachidonic acid metabolism as a therapeutic target in AKI-to-CKD transition.Frontiers in pharmacology · 2024Review
- Umbelliferone and Its Synthetic Derivatives as Suitable Molecules for the Development of Agents with Biological Activities: A Review of Their Pharmacological and Therapeutic Potential.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Transgenic mice overexpressing human ALOX15 under the control of the aP2 promoter are partly protected in the complete Freund's adjuvant-induced paw inflammation model.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Article
- Hydroxychavicol as a potential anticancer agent (Review).Oncology letters · 2023Review
- Machine learning in metastatic cancer research: Potentials, possibilities, and prospects.Computational and structural biotechnology journal · 2023Review
- Correlation between Metabolite of Prostaglandin E2 and the incidence of colorectal adenomas.Frontiers in oncology · 2023Article
- Recent insights into dietary ω-6 fatty acid health implications using a systematic review.Food science and biotechnology · 2022Review
- Multi-Omics Approach Points to the Importance of Oxylipins Metabolism in Early-Stage Breast Cancer.Cancers · 2022Article
- Gypenoside L and Gypenoside LI Inhibit Proliferation in Renal Cell CarcinomaFrontiers in pharmacology · 2022Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Cancer initiation and progression are multistep events that require cell proliferation, migration, extravasation to the blood or lymphatic vessels, arrest to the metastatic site, and ultimately secondary growth. Tumor cell functions at both primary or secondary sites are controlled by many different factors, including growth factors and their receptors, chemokines, nuclear receptors, cell-cell interactions, cell-matrix interactions, as well as oxygenated metabolites of arachidonic acid. The observation that cyclooxygenases and lipoxygenases and their arachidonic acid-derived eicosanoid products (prostanoids and HETEs) are expressed and produced by tumor cells, together with the finding that these enzymes can regulate cell growth, survival, migration, and invasion, has prompted investigators to analyze the roles of these enzymes in cancer progression. In this review, we focus on the contribution of cyclooxygenase- and lipoxygenase-derived eicosanoids to tumor cell function in vitro and in vivo and discuss hope and tribulations of targeting these enzymes for cancer prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.